News & Media

MEDIAN Technologies to Present Study Results at the ESMO 2014 Congress in Madrid

24 September 2014, Sophia Antipolis, France
  • MEDIAN Technologies will present results of a study dealing with the utilization of lesion volume, an imaging biomarker for the evaluation of hepatic tumors.
  • The MEDIAN team will be available at Booth 170 to present the company’s offer for image interpretation and management in oncology trials.

MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs, and routine practice in oncology, today announced its participation in the annual congress of the European Society for Medical Oncology (ESMO), to be held September 26-30, in Madrid, Spain.

During the ESMO Congress, the premier oncology congress in Europe, MEDIAN’s scientists will present the results of the study, “Monitoring of Hepatic Tumors on Computed Tomography: Quantifiable Target Lesions and Variability of Volume-based Assessments.” Response Evaluation Criteria in Solid Tumors (RECIST) remain a standard in oncology imaging. However, as an alternative to RECIST, lesion volumetry is promising and expected to anticipate response to therapy, because it is less variable and more sensitive than RECIST. Lung lesion volume as a quantitative imaging biomarker is significantly documented in the literature, but few studies investigating other sites of disease such as the liver are available. In this study, we assessed inter-reader variability in measuring volume of hepatic lesions and investigated reliability of assessments of hepatic lesion sub-populations. Study results will be presented at the ESMO poster display session “Imaging, Diagnosis and Staging – Translational Research,” planned on September 28th from 12:45 to 1:45 pm in the poster area.

The study abstract is available online (abstract #1626P): https://www.webges.com/cslide/library/esmo/browse/search/7SB#9faD03ap

MEDIAN’s scientific and business development teams will also be available at Booth 170 to discuss study results, to give demonstrations of MEDIAN’s Lesion Management Solutions (LMS), and to present MEDIAN’s offer for image interpretation and management in oncology trials. The industry exhibition opening times are Sept 27, Sep 28 and Sept 29 from 8:30 to 17:00.

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”

Contacts

MEDIAN Technologies

Fredrik Brag
CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66
median@alizerp.com

Cookies help us deliver our services. By using our services, you agree to our use of cookies.